Biotech PolyNovo managing director Paul Brennan says predicting the sales trajectory in its key market the United States is “challenging” after revealing revenue growth for its skin regeneration technology had slowed in the second quarter as hospital capacity was filled by surging COVID-19 cases.
The $1.95 billion company makes dermal regeneration solutions, NovoSorb BTM, using its NovoSorb biodegradable polymer technology.
Loading...
Carrie LaFrenz is a senior journalist covering retail/consumer goods. She previously covered healthcare/biotech. Carrie has won multiple awards for her journalism including financial journalist of the year from The National Press Club. Connect with Carrie on Twitter. Email Carrie at carrie.lafrenz@afr.com
